PROCEPT BioRobotics (PRCT) Earnings Call Presentation

Key Milestones & Financials - PROCEPT BioRobotics achieved global revenue of $224.5 million in 2024[15] - The company's revenue guidance for 2025 is $323 million[18] - In 2021, PROCEPT BioRobotics had an IPO at $1.2 billion market capitalization[12] HYDROS System & Commercial Update - HYDROS resonates with all BPH hospitals, with a 20% BPH hospital penetration rate[31] - The U.S. install base shows a shift from 1Q23 to 1Q25, with low-volume hospitals decreasing from 73% to 61%, medium-volume increasing from 6% to 8%, and high-volume increasing from 20% to 31%[30] Prostate Cancer & Aquablation Therapy - Approximately 60% of Active Surveillance patients will undergo radical treatment in 10-15 years[100] - In the U.S., 26% of localized prostate cancer diagnoses are high risk, 50% are intermediate risk, and 24% are low risk[79] - Early data from PRCT001 + PRCT002 trials includes 88 prostate cancer patients treated, with 65 having 3-month follow-up and 47 having 6-month follow-up[125] - 70% of prostate cancer patients in PRCT001 + PRCT002 have intermediate-risk disease[127] - 76% of patients in PRCT001 + PRCT002 have cancer in the Peripheral Zone[130]